Clinical trial Recruiting at 1 site Observational

Registry of Parkinson's disease patients with LRRK2 gene variants in China

Official title: The Chinese Parkinson's Disease With LRRK2 Variants Registry

Run by Xiangya Hospital of Central South University · NCT03523104 · Data updated 2026-11-12

This study is creating a database to learn more about Parkinson's disease in people with specific LRRK2 gene changes in China by collecting health information and blood samples.

More Parkinson Disease trials

Quick facts

Study typeObservational
SexAll
Enrollment1000 (estimated)
SponsorXiangya Hospital of Central South University
Academic / other
Locations1 site (Changsha, Hunan)
StatusRecruiting
StartedFebruary 1, 2017
Main results expectedFebruary 1, 2027
Study endsFebruary 1, 2027
Registry record updatedMay 29, 2018
Trial IDNCT03523104 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this registry are patients diagnosed with Parkinson's disease who have tested positive for LRRK2 gene variants.

Probably not a fit

Patients without a diagnosis of Parkinson's disease or those who do not have LRRK2 gene variants may not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Chinese PD-LRRK2 Registry aims to create a comprehensive database of patients diagnosed with Parkinson's disease (PD) who have specific LRRK2 gene variants. This observational study will collect clinical data and assess the manifestations of PD using various standardized scales and neurological tests. Additionally, blood samples will be analyzed for biomarkers associated with PD, such as uric acid and inflammatory markers. The goal is to better understand the clinical characteristics of PD patients with LRRK2 variants in mainland China.

Why it matters

Potential benefit: If successful, this registry could enhance understanding of Parkinson's disease and improve personalized treatment strategies for patients with LRRK2 gene variants.

How similar studies have gone: While there have been studies on LRRK2 variants in Parkinson's disease, this registry approach is relatively novel in the context of mainland China.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria or other standard criteria; PD patients detected with positive LRRK2 variants

Exclusion Criteria:

\-

Where it's running

  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.